+
For instructor materials including Power Points, Answers to Clinical Encounter Questions, please contact [email protected].
++
Content Update
July 04, 2025
2024 Updated Guidance on the Management of Resistant Gram-Negative Infections by Infectious Diseases Society of America, Part 1: The 2024 IDSA guidance on the management of resistant gram-negative infections was developed in effort to provide expert-guided recommendations given the limited, robust clinical data. Resistant gram-negative infections addressed in this guidance document include extended spectrum β-lactamase (ESBL), AmpC β-lactamase (AmpC), carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa with difficult-to-treat resistance (DTR P. aeruginosa), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia. In this part one of two-part update, the management of infections due to ESBL, AmpC, and DTR P. aeruginosa is discussed.
++
Content Update
July 04, 2025
2024 Updated Guidance on the Management of Resistant Gram-Negative Infections by Infectious Diseases Society of America, Part 2: The 2024 IDSA guidance on the management of resistant gram-negative infections was developed in effort to provide expert-guided recommendations given the limited, robust clinical data. Resistant gram-negative infections addressed in this guidance document include extended spectrum β-lactamase (ESBL), AmpC β-lactamase (AmpC), carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa with difficult-to-treat resistance (DTR P. aeruginosa), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia. In this one of two-part update, the management of infections due to CRE, CRAB and S. maltophilia is discussed.
++
Content Update
July 02, 2025
Gepotidacin: A Novel Drug for Uncomplicated Urinary Tract Infections: Gepotidacin is a type IIA topoisomerase inhibitor approved for the treatment of uncomplicated urinary tract infections (UTIs) in nonpregnant women and girls 12 years or older weighing greater than 40 kg. Oral gepotidacin is an alternative option that can be utilized in patients with contraindications to first-line agents or UTIs that are resistant to those agents. Gepotidacin should be carefully utilized, following evidence-based guidelines and antimicrobial stewardship to prevent further resistance that could emerge from overuse in the community.
++
Content Update
December 18, 2024
Cefepime/enmetazobactam in the treatment of complicated urinary tract infections or acute pyelonephritis: Cefepime/enmetazobactam combines a fourth-generation cephalosporin with a novel beta lactamase inhibitor and is approved the U.S. Food and Drug Administration for complicated urinary tract infections or acute pyelonephritis. This combination antibiotic will provide an additional option for multidrug-resistant gram-negative pathogens.
++
Content Update
June 24, 2024
Pivmecillinam: A Newly Approved Penicillin Antibiotic: In April of 2024, the beta-lactam antibiotic, pivmecillinam, a prodrug of mecillinam, was approved by the United States Food and Drug Administration for the treatment of uncomplicated urinary tract infections in female adults 18 years of age and older.
++
Content Update
June 14, 2024
Ceftobiprole: A newly approved cephalosporin antibiotic: Effective treatment against bacterial infections is increasingly difficult as antimicrobial resistance is on the rise. Ceftobiprole medocaril, a 5th-generation cephalosporin, was recently approved by the U.S. Food and Drug Administration for the treatment of Staphylococcus aureus bacteremia (SAB), acute bacterial ...